Erlichman, C <br/><br/>
The HER tyrosine kinase inhibitor CI1033 enhances cytotoxicity of 7-ethyl-10-hydroxycamptothecin and topotecan by inhibiting breast cancer resistance protein-mediated drug efflux.  [electronic resource] 

 -  Cancer research  Jan 2001 
 - 739-48 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, U.S. Gov't, P.H.S. 
<br/><br/><label>ISSN: </label>0008-5472 
<br/><br/><label>Subjects--Topical Terms: </label><br/>ATP Binding Cassette Transporter, Subfamily G, Member 2<br/>ATP-Binding Cassette Transporters--genetics<br/>Antineoplastic Agents--pharmacology<br/>Biological Transport--drug effects<br/>Camptothecin--analogs & derivatives<br/>Cell Cycle--drug effects<br/>Dose-Response Relationship, Drug<br/>Drug Interactions<br/>Drug Resistance, Neoplasm<br/>Drug Synergism<br/>Enzyme Inhibitors--pharmacology<br/>ErbB Receptors--drug effects<br/>Humans<br/>Irinotecan<br/>Morpholines--pharmacology<br/>Neoplasm Proteins<br/>Neoplastic Stem Cells--drug effects<br/>Phosphorylation--drug effects<br/>Protein-Tyrosine Kinases--antagonists & inhibitors<br/>Recombinant Fusion Proteins--genetics<br/>Topoisomerase I Inhibitors<br/>Topotecan--metabolism<br/>Transfection<br/>Tumor Cells, Cultured<br/>Tumor Stem Cell Assay